Alongside GlaxoSmithKline, I’d buy this growing share in the healthcare sector

I reckon this company looks well-positioned to trade through the coronavirus crisis with reduced revenues.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Pharmaceutical giant GlaxoSmithKline has defensive, cash-generating credentials that I admire. But it’s not the only share I’d buy in the wider healthcare sector.

Today’s half-year results report from CVS (LSE: CVSG) contains decent growth figures. The company provides integrated veterinary services in the UK, and the directors describe the sector as having “considerable resilience.” But there have been problems. Just over a year ago, the company’s profits were on the floor.

After a strong recovery in the second half of the trading year to June 2019, today’s numbers mark a return to solid growth. Revenue rose by just over 15% compared to the equivalent period in the prior year, and adjusted earnings per share shot up by 30%. Within the revenue figure, like-for-like sales moved up by more than 8%, suggesting robust organic progress.

Expanding steadily

On top of that, CVS has been expanding via acquisitions. Five practice surgeries joined the company in the period as a result of three bolt-on takeovers. To put that expansion in perspective, the company has over 500 practices, more than 1,800 vets, and around 2,300 nurses.

Of course, the immediate future is uncertain because of the coronavirus pandemic. Since the lockdown in the UK, veterinary practices can only remain open for urgent and emergency care. The firm is handling non-urgent and non-emergency cases via “teleconsultation.” 

The consequence of that is “a significant reduction” in both small animal billable visits and revenue. CVS has temporarily closed half its small animal practices, which represents around one-third of its capacity in that area of operations. Meanwhile, teleconsultations with clients for non-urgent or non-emergency cases are charged at “normal consultation rates.”  

However, all the company’s referral hospitals, laboratories, and crematoria are staying open to provide essential patient care and for clinical waste collection. The company reckons around 40% of its small animal client base is in the Healthy Pet Club, which provides “some degree” of revenue visibility. Meanwhile, the online business is “fully operational” and is seeing “record levels” of food and medicine sales. 

Trading through the crisis

I reckon CVS looks well-positioned to trade through the crisis even if revenues end up reducing. As such, the company seems to be luckier than firms in some sectors that have been closed down altogether.

Looking ahead, the directors acknowledge that the full effects of the pandemic remain unknown. However, they are “confident” that the firm is doing everything it can to protect its employees, maintain business operations, and preserve cash and income streams.

My guess is that CVS will prove to be a strong survivor of the crisis. And I’m inclined to view weakness in the share price now as an opportunity to buy the shares for the longer-term growth story. At 755p, the share price is around 37% lower than it was on 20 February.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin Godbold has no position in any share mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

2 high-yield FTSE 250 shares I’d buy today — and 1 that I’d avoid

UK markets have felt some volatility after last week’s Budget and the FTSE 250 was no stranger to it. Our…

Read more »

Investing Articles

3 reasons the Rolls-Royce share price could soar over the next decade

Sustainable aviation fuel, narrow-body aircraft, and small nuclear reactors could all keep the Rolls-Royce share price climbing over the next…

Read more »

British flag, Big Ben, Houses of Parliament and British flag composition
Investing Articles

Here’s how much income I’d get if I invested my entire £20k ISA in cheap BT shares

BT shares are on the up but still cheap, while the FTSE 100 telecoms stock offers a good yield too.…

Read more »

Investing Articles

2 FTSE dividend shares yielding more than 6% with P/Es of less than 9!

Harvey Jones picks out two brilliant FTSE 100 dividend shares that yield more than 6% but are selling at strangely…

Read more »

Investing Articles

Up 105% in a year! Is this rocketing FTSE bank the perfect pick for my Stocks and Shares ISA?

Harvey Jones is drawing up a shortlist of stocks to purchase inside his Stocks and Shares ISA allowance. This FTSE…

Read more »

Investing Articles

Down 78%, is this once-hot AI growth stock set to explode like the Rolls-Royce share price?

Our writer asks if he should invest in Super Micro Computer (NASDAQ:SMCI) following the growth stock's massive recent decline.

Read more »

Investing Articles

Is it madness to buy Palantir shares after Q3 earnings?

Palantir stock's surging again after the firm's Q3 earnings report. But after a 150% gain, is it too late to…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

£6,000 in savings? Here’s how I’d aim to turn that into £1,032 a month of passive income!

A small investment in high-dividend-paying stocks with the returns used to buy more shares can generate big passive income over…

Read more »